These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29337222)

  • 1. Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease.
    Gu JM; Yuan S; Sim D; Abe K; Liu P; Rosenbruch M; Bringmann P; Kauser K
    Exp Hematol; 2018 Apr; 60():73-82.e3. PubMed ID: 29337222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placenta growth factor activates monocytes and correlates with sickle cell disease severity.
    Perelman N; Selvaraj SK; Batra S; Luck LR; Erdreich-Epstein A; Coates TD; Kalra VK; Malik P
    Blood; 2003 Aug; 102(4):1506-14. PubMed ID: 12714517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions.
    Jang JE; Hod EA; Spitalnik SL; Frenette PS
    J Clin Invest; 2011 Apr; 121(4):1397-401. PubMed ID: 21383500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Mac-1-mediated leukocyte-RBC interactions uncouples the benefits for acute vaso-occlusion and chronic organ damage.
    Chen G; Chang J; Zhang D; Pinho S; Jang JE; Frenette PS
    Exp Hematol; 2016 Oct; 44(10):940-6. PubMed ID: 27393574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease.
    Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM
    Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease.
    Gonsalves CS; Li C; Mpollo MS; Pullarkat V; Malik P; Tahara SM; Kalra VK
    Biochem J; 2015 Jun; 468(3):409-23. PubMed ID: 25876995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70.
    Adewoye AH; Klings ES; Farber HW; Palaima E; Bausero MA; McMahon L; Odhiambo A; Surinder S; Yoder M; Steinberg MH; Asea A
    Am J Hematol; 2005 Mar; 78(3):240-2. PubMed ID: 15726596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD.
    Liu Y; Zhong H; Bao W; Mendelson A; An X; Shi P; Chou ST; Manwani D; Yazdanbakhsh K
    Blood; 2019 Aug; 134(7):579-590. PubMed ID: 31076443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
    Tchernychev B; Li H; Lee SK; Gao X; Ramanarasimhaiah R; Liu G; Hall KC; Bernier SG; Jones JE; Feil S; Feil R; Buys ES; Graul RM; Frenette PS; Masferrer JL
    Br J Pharmacol; 2021 Sep; 178(17):3463-3475. PubMed ID: 33864386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).
    Elshazly SA; Heiba NM; Abdelmageed WM
    Hematology; 2014 Jan; 19(1):52-9. PubMed ID: 23735470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report.
    Ahmed S; Siddiqui AK; Iqbal U; Sison CP; Shahid RK; Sheth M; Patel DV; Russo LA
    Eur J Haematol; 2004 Mar; 72(3):213-6. PubMed ID: 14962240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine profile of sickle cell disease in Oman.
    Pathare A; Al Kindi S; Alnaqdy AA; Daar S; Knox-Macaulay H; Dennison D
    Am J Hematol; 2004 Dec; 77(4):323-8. PubMed ID: 15551290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.
    Rossato P; Federti E; Matte A; Glantschnig H; Canneva F; Schuster M; Coulibaly S; Schrenk G; Voelkel D; Dockal M; Plaimauer B; Andolfo I; Iolascon A; Rottensteiner H; Gritsch H; Scheiflinger F; Hoellriegl W; Franceschi L
    Haematologica; 2022 Nov; 107(11):2650-2660. PubMed ID: 35443560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
    Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
    Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse Models of Pain in Sickle Cell Disease.
    Sagi V; Song-Naba WL; Benson BA; Joshi SS; Gupta K
    Curr Protoc Neurosci; 2018 Oct; 85(1):e54. PubMed ID: 30265442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemolysis dictates monocyte differentiation via two distinct pathways in sickle cell disease vaso-occlusion.
    Liu Y; Su S; Shayo S; Bao W; Pal M; Dou K; Shi PA; Aygun B; Campbell-Lee S; Lobo CA; Mendelson A; An X; Manwani D; Zhong H; Yazdanbakhsh K
    J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37490346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quercetin Completely Ameliorates Hypoxia-Reoxygenation-Induced Pathophysiology Severity in NY1DD Transgenic Sickle Mice: Intrinsic Mild Steady State Pathophysiology of the Disease in NY1DD Is Also Reversed.
    Thangaswamy S; Branch CA; Ambadipudi K; Acharya SA
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
    Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
    Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia/reoxygenation stress increases markers of vaso-occlusive crisis in sickle SAD mice.
    Aufradet E; DeSouza G; Bourgeaux V; Bessaad A; Campion Y; Canet-Soulas E; Pialoux V; Chirico EN; Chevrier AM; Godfrin Y; Martin C
    Clin Hemorheol Microcirc; 2013 Jan; 54(3):297-312. PubMed ID: 23696418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.